Shanghai CRO Service Alliance Adds Clinical Development Capabilities
Tigermed Consulting joins Shanghai CRO Service Alliance, CROSA.
Shanghai, China-April 30, 2008-Today, Tigermed Consulting Ltd. ( www.tigermed.net ) joins Sundia Meditech ( www.sundia.com ), HD BioSciences ( www.hdbiosciences.com ), and NovaSecta ( www.novasecta.com ) in their CRO Service Alliance CROSA that provides R&D solutions for pharmaceutical and biotech companies. Tigermed’s expertise in clinical development complements the existing drug discovery and pharmaceutical development capabilities of the alliance.
Sundia Meditech, United PharmaTech, and HD BioSciences entered into a CRO Service Alliance in May 2007 in order to quickly and successfully integrate their chemistry and biology expertise for the increased demands from their clients world-wide. Sundia and United merged into one company in the following months. NovaSecta joined the alliance in February 2008 to further integrate the alliance’s work with European pharmaceutical and biotech companies.
Tigermed has a strong track record of providing clinical development services, data management, and statistical support to multinational and smaller to medium sized pharmaceutical and biotech companies in the US, Europe, and Asia. Tigermed is also the clear leader in performing clinical trials in China on innovative New Chemical Entities (NCEs), which makes it an excellent potential partner for the pharmaceutical and biotech companies that Sundia, HD BioSciences, and NovaSecta work with.
Through the addition of Tigermed to the alliance, clients can now benefit from a seamlessly integrated full R&D service covering discovery, non-clinical and clinical development.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
